Exact Mass: 646.4139

Exact Mass Matches: 646.4139

Found 111 metabolites which its exact mass value is equals to given mass value 646.4139, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

PA(13:0/18:1(12Z)-O(9S,10R))

[(2R)-2-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]-3-(tridecanoyloxy)propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(13:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(12Z)-O(9S,10R)/13:0)

[(2R)-3-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]-2-(tridecanoyloxy)propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(18:1(12Z)-O(9S,10R)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/13:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/18:1(9Z)-O(12,13))

[(2R)-2-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(13:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(9Z)-O(12,13)/13:0)

[(2R)-3-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(18:1(9Z)-O(12,13)/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/13:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/18:1(12Z)-O(9S,10R))

[(2R)-3-[(10-methyldodecanoyl)oxy]-2-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(a-13:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(12Z)-O(9S,10R)/a-13:0)

[(2R)-2-[(10-methyldodecanoyl)oxy]-3-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(18:1(12Z)-O(9S,10R)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/a-13:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/18:1(9Z)-O(12,13))

[(2R)-3-[(10-methyldodecanoyl)oxy]-2-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(a-13:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(9Z)-O(12,13)/a-13:0)

[(2R)-2-[(10-methyldodecanoyl)oxy]-3-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(18:1(9Z)-O(12,13)/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/a-13:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/18:1(12Z)-O(9S,10R))

[(2R)-3-[(11-methyldodecanoyl)oxy]-2-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(i-13:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(12Z)-O(9S,10R)/i-13:0)

[(2R)-2-[(11-methyldodecanoyl)oxy]-3-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(18:1(12Z)-O(9S,10R)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/i-13:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/18:1(9Z)-O(12,13))

[(2R)-3-[(11-methyldodecanoyl)oxy]-2-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(i-13:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(9Z)-O(12,13)/i-13:0)

[(2R)-2-[(11-methyldodecanoyl)oxy]-3-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}propoxy]phosphonic acid

C34H63O9P (646.4209)


PA(18:1(9Z)-O(12,13)/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/i-13:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Ascosteroside

Ascosteroside

C37H58O9 (646.4081)


   

(+)-12alpha,28-Dihydroxy-3alpha-(3-hydroxy-3-methylglutaryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid

(+)-12alpha,28-Dihydroxy-3alpha-(3-hydroxy-3-methylglutaryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid

C37H58O9 (646.4081)


   

Laetiposide D

Laetiposide D

C37H58O9 (646.4081)


   
   

3-O-beta-D-xylopyranosyl-16beta-acetoxyholost-7-ene

3-O-beta-D-xylopyranosyl-16beta-acetoxyholost-7-ene

C37H58O9 (646.4081)


   

micromonospolide B

micromonospolide B

C37H58O9 (646.4081)


   

Oleanolic acid-3-O-??-D-(6-O-methyl)-glucuronoside

Oleanolic acid-3-O-??-D-(6-O-methyl)-glucuronoside

C37H58O9 (646.4081)


   

25-methoxy-5beta,19-epoxycucurbita-6,23-dien-19-on-3beta-ol 3-O-beta-D-glucopyranoside|karaviloside VI

25-methoxy-5beta,19-epoxycucurbita-6,23-dien-19-on-3beta-ol 3-O-beta-D-glucopyranoside|karaviloside VI

C37H58O9 (646.4081)


   

Prostratoside I

Prostratoside I

C37H58O9 (646.4081)


   

3-O-(2-O-Acetyl-alpha-L-arabinopyranoside)-3,23-Dihydroxy-12-oleanen-28-oic acid

3-O-(2-O-Acetyl-alpha-L-arabinopyranoside)-3,23-Dihydroxy-12-oleanen-28-oic acid

C37H58O9 (646.4081)


   

3beta-hydroxyurs-12-en-28-oic acid 3-O-beta-D-glucuranopyranoside 6-O-methyl ester

3beta-hydroxyurs-12-en-28-oic acid 3-O-beta-D-glucuranopyranoside 6-O-methyl ester

C37H58O9 (646.4081)


   

3beta-O-cis-ferulyl-2alpha-hydroxy-urs-12-en-28-oic acid

3beta-O-cis-ferulyl-2alpha-hydroxy-urs-12-en-28-oic acid

C41H58O6 (646.4233)


   

28-acetoxy-olean-12-en-3beta-yl trans-caffeate

28-acetoxy-olean-12-en-3beta-yl trans-caffeate

C41H58O6 (646.4233)


   

3-[(2-O-acetyl-beta-D-xylopyranosyl)oxy]-19-hydroxyurs-12-en-28-oic acid|ilexasprellanoside B

3-[(2-O-acetyl-beta-D-xylopyranosyl)oxy]-19-hydroxyurs-12-en-28-oic acid|ilexasprellanoside B

C37H58O9 (646.4081)


   

(19alpha)-3-[(2-O-acetyl-beta-D-xylopyranosyl)oxy]-19-hydroxyolean-12-en-28-oic acid|ilexasprellanoside E

(19alpha)-3-[(2-O-acetyl-beta-D-xylopyranosyl)oxy]-19-hydroxyolean-12-en-28-oic acid|ilexasprellanoside E

C37H58O9 (646.4081)


   

Fomitoside E

Fomitoside E

C37H58O9 (646.4081)


A triterpene glycoside that consists of lanost-8,23-dien-21-oic acid substituted at by a alpha-acetyloxy group at position 3, a hydroxy group at position 25 and a beta-D-xylopyranosyl moiety at position 21 via a glycosidic linkage. Isolated from the fruit body of Fomitopsis pinicola, it exhibits inhibitory activity against COX-1 and COX-2.

   

3-O-acetyl-3-O-alpha-L-arabinopyranosyl hederagenin|3-O-acetyl-3-O-alpha-L-arabinosyl-23-hydroxyolean-12-en-28-oic acid

3-O-acetyl-3-O-alpha-L-arabinopyranosyl hederagenin|3-O-acetyl-3-O-alpha-L-arabinosyl-23-hydroxyolean-12-en-28-oic acid

C37H58O9 (646.4081)


   

4-O-acetyl-3-O-alpha-L-arabinopyranosyl hederagenin|4-O-acetyl-3-O-alpha-L-arabinosyl-23-hydroxyolean-12-en-28-oic acid

4-O-acetyl-3-O-alpha-L-arabinopyranosyl hederagenin|4-O-acetyl-3-O-alpha-L-arabinosyl-23-hydroxyolean-12-en-28-oic acid

C37H58O9 (646.4081)


   

Cloversaponin I methyl ester

Cloversaponin I methyl ester

C37H58O9 (646.4081)


   

Prostaglandin A1-biotin

N-9-oxo-15S-hydroxy-prosta-10,13E-dien-1-oyl-N-biotinoyl-1,6-diaminopentane

C35H58N4O5S (646.4128)


   

Humionoactoside A

(6R,9S)-9-O-beta-D-glucopyranosyloxy-6-O- ([Z,1Z,1Z]-triene)-octadeca-6-hydroxy-9-methyl-3-oxo-alpha-ionol

C37H58O9 (646.4081)


   

butyl 2-methylprop-2-enoate,2-ethylhexyl prop-2-enoate,2-hydroxyethyl prop-2-enoate,methyl 2-methylprop-2-enoate,styrene

butyl 2-methylprop-2-enoate,2-ethylhexyl prop-2-enoate,2-hydroxyethyl prop-2-enoate,methyl 2-methylprop-2-enoate,styrene

C37H58O9 (646.4081)


   

Fruticoside D

Fruticoside D

C37H58O9 (646.4081)


A steroid saponin that is 4-methylergosta-7,24(28)-dien-21-oic acid attached to an acetyloxy group at position 2, and a alpha-L-quinovopyranosyloxy group at position 3 (the 2alpha,3beta,4alpha,5alpha stereoisomer). It has been isolated from the roots of Breynia fruticosa.

   

Fruticoside E

Fruticoside E

C37H58O9 (646.4081)


A steroid saponin that is 4-methylergosta-7,24(28)-dien-21-oic acid attached to an acetyloxy group at position 2, and a alpha-L-rhamnopyranosyloxy group at position 3 (the 2alpha,3beta,4alpha,5alpha stereoisomer). It has been isolated from the roots of Breynia fruticosa.

   

PA(13:0/18:1(12Z)-O(9S,10R))

PA(13:0/18:1(12Z)-O(9S,10R))

C34H63O9P (646.4209)


   

PA(18:1(12Z)-O(9S,10R)/13:0)

PA(18:1(12Z)-O(9S,10R)/13:0)

C34H63O9P (646.4209)


   

PA(a-13:0/18:1(12Z)-O(9S,10R))

PA(a-13:0/18:1(12Z)-O(9S,10R))

C34H63O9P (646.4209)


   

PA(18:1(12Z)-O(9S,10R)/a-13:0)

PA(18:1(12Z)-O(9S,10R)/a-13:0)

C34H63O9P (646.4209)


   

PA(a-13:0/18:1(9Z)-O(12,13))

PA(a-13:0/18:1(9Z)-O(12,13))

C34H63O9P (646.4209)


   

PA(18:1(9Z)-O(12,13)/a-13:0)

PA(18:1(9Z)-O(12,13)/a-13:0)

C34H63O9P (646.4209)


   

PA(i-13:0/18:1(12Z)-O(9S,10R))

PA(i-13:0/18:1(12Z)-O(9S,10R))

C34H63O9P (646.4209)


   

PA(18:1(12Z)-O(9S,10R)/i-13:0)

PA(18:1(12Z)-O(9S,10R)/i-13:0)

C34H63O9P (646.4209)


   

PA(i-13:0/18:1(9Z)-O(12,13))

PA(i-13:0/18:1(9Z)-O(12,13))

C34H63O9P (646.4209)


   

PA(18:1(9Z)-O(12,13)/i-13:0)

PA(18:1(9Z)-O(12,13)/i-13:0)

C34H63O9P (646.4209)


   

[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropyl] tridecanoate

[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropyl] tridecanoate

C34H63O9P (646.4209)


   

[(2R)-1-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] tridecanoate

[(2R)-1-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] tridecanoate

C34H63O9P (646.4209)


   

Mgdg O-26:7_2:0

Mgdg O-26:7_2:0

C37H58O9 (646.4081)


   

PE-Cer 12:2;2O/22:6

PE-Cer 12:2;2O/22:6

C36H59N2O6P (646.4111)


   

PE-Cer 16:3;2O/18:5

PE-Cer 16:3;2O/18:5

C36H59N2O6P (646.4111)


   

PE-Cer 14:3;2O/20:5

PE-Cer 14:3;2O/20:5

C36H59N2O6P (646.4111)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] decanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] decanoate

C34H63O9P (646.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] dodecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] dodecanoate

C34H63O9P (646.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C34H63O9P (646.4209)


   

[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C34H63O9P (646.4209)


   

TG(38:10)

TG(6:0_10:4_22:6)

C41H58O6 (646.4233)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

MGDG O-28:7

MGDG O-28:7

C37H58O9 (646.4081)


   
   

PA O-18:0/13:3;O2

PA O-18:0/13:3;O2

C34H63O9P (646.4209)


   
   

PA 20:0/11:2;O

PA 20:0/11:2;O

C34H63O9P (646.4209)


   

PA 22:1/9:1;O

PA 22:1/9:1;O

C34H63O9P (646.4209)


   
   
   
   

6-{7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

6-{7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

C37H58O9 (646.4081)


   

3,4,5-trihydroxyoxan-2-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylhept-4-enoate

3,4,5-trihydroxyoxan-2-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylhept-4-enoate

C37H58O9 (646.4081)


   

6-[(4e,6e,12e,14e)-3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[(4e,6e,12e,14e)-3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C37H58O9 (646.4081)


   

(1r,4s,5s,8r,9r,12s,13s,16s)-8-[(2r,4e)-6-methoxy-6-methylhept-4-en-2-yl]-5,9,17,17-tetramethyl-16-{[(2r,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one

(1r,4s,5s,8r,9r,12s,13s,16s)-8-[(2r,4e)-6-methoxy-6-methylhept-4-en-2-yl]-5,9,17,17-tetramethyl-16-{[(2r,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one

C37H58O9 (646.4081)


   

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4s,5s)-4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4s,5s)-4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

6-[(4e,6e,12e,14e)-3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

6-[(4e,6e,12e,14e)-3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl]-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-hydroxypyran-4-one

C37H58O9 (646.4081)


   

6-[(2r,3s,4e,6e,8r,9r,10s,12e,14z,16s,18r)-3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl]-3-[(2r,3s,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-[(2r,3s,4e,6e,8r,9r,10s,12e,14z,16s,18r)-3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl]-3-[(2r,3s,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C37H58O9 (646.4081)


   

2-(3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl)-6-methyl-5-methylideneheptanoic acid

2-(3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl)-6-methyl-5-methylideneheptanoic acid

C37H58O9 (646.4081)


   

(1r,3r,3as,5ar,7s,11ar)-7-{[(2r,3r,4r,5s,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

(1r,3r,3as,5ar,7s,11ar)-7-{[(2r,3r,4r,5s,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

C37H58O9 (646.4081)


   

2,6,13,17,17-pentamethyl-6-(4-methylpentyl)-8-oxo-16-[(3,4,5-trihydroxyoxan-2-yl)oxy]-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-1(20)-en-4-yl acetate

2,6,13,17,17-pentamethyl-6-(4-methylpentyl)-8-oxo-16-[(3,4,5-trihydroxyoxan-2-yl)oxy]-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-1(20)-en-4-yl acetate

C37H58O9 (646.4081)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(3r,3ar,6s,7s,9br)-6-(3-methoxy-3-oxopropyl)-3a,6,9b-trimethyl-7-(prop-1-en-2-yl)-1h,2h,3h,4h,5h,7h,8h,9h-cyclopenta[a]naphthalen-3-yl]-6-methylhept-5-enoate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(3r,3ar,6s,7s,9br)-6-(3-methoxy-3-oxopropyl)-3a,6,9b-trimethyl-7-(prop-1-en-2-yl)-1h,2h,3h,4h,5h,7h,8h,9h-cyclopenta[a]naphthalen-3-yl]-6-methylhept-5-enoate

C37H58O9 (646.4081)


   

6-{7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

6-{7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

C37H58O9 (646.4081)


   

(1r,3r,3as,5ar,7s,9as,11ar)-7-{[(2r,3r,4r,5s,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

(1r,3r,3as,5ar,7s,9as,11ar)-7-{[(2r,3r,4r,5s,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

C37H58O9 (646.4081)


   

10-{[4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

10-{[4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(2s,6r)-6-[(1r,3as,5ar,6s,7r,9as,11s,11ar)-7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,6s,7r,9as,11s,11ar)-7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O9 (646.4081)


   

8-(6-methoxy-6-methylhept-4-en-2-yl)-5,9,17,17-tetramethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one

8-(6-methoxy-6-methylhept-4-en-2-yl)-5,9,17,17-tetramethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one

C37H58O9 (646.4081)


   

(3e,5z,7r,8s,9s,11z,13z,15s,16r)-16-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-[(1e,3e)-penta-1,3-dien-1-yl]oxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

(3e,5z,7r,8s,9s,11z,13z,15s,16r)-16-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-[(1e,3e)-penta-1,3-dien-1-yl]oxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

C37H58O9 (646.4081)


   

(4as,6as,6br,8ar,10s,12ar,12br,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,10s,12ar,12br,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(1s,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-1,2,6a,6b,9,9,12a-heptamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

(1s,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-1,2,6a,6b,9,9,12a-heptamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(2r)-2-[(1r,3ar,4r,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

(2r)-2-[(1r,3ar,4r,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

C37H58O9 (646.4081)


   

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4s,5s)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4s,5s)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(2s,6r)-6-[(1r,3as,5r,5ar,7s,9as,11s,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5r,5ar,7s,9as,11s,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-5,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O9 (646.4081)


   

1,2,6a,6b,9,9,12a-heptamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

1,2,6a,6b,9,9,12a-heptamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

C37H58O9 (646.4081)


   

6-(3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl)-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

6-(3,9-dihydroxy-6,8,10,14,16,18-hexamethylicosa-4,6,12,14-tetraen-2-yl)-3-[3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxypyran-2-one

C37H58O9 (646.4081)


   

(2s,6r)-6-[(1r,3as,5ar,6s,7r,9as,11s,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,6s,7r,9as,11s,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O9 (646.4081)


   

10-{[5-(acetyloxy)-3,4-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

10-{[5-(acetyloxy)-3,4-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(2r)-2-[(1r,3ar,4s,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

(2r)-2-[(1r,3ar,4s,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

C37H58O9 (646.4081)


   

(1r,4s,5s,8r,9r,12s,13s,16s)-8-[(2r,4e)-6-methoxy-6-methylhept-4-en-2-yl]-5,9,17,17-tetramethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one

(1r,4s,5s,8r,9r,12s,13s,16s)-8-[(2r,4e)-6-methoxy-6-methylhept-4-en-2-yl]-5,9,17,17-tetramethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one

C37H58O9 (646.4081)


   

(1s,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-1,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

(1s,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-1,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

C37H58O9 (646.4081)


   

2,4,5-trihydroxyoxan-3-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylhept-4-enoate

2,4,5-trihydroxyoxan-3-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylhept-4-enoate

C37H58O9 (646.4081)


   

10-{[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

10-{[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(1r,3r,3as,5ar,7s,9as,11ar)-7-{[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

(1r,3r,3as,5ar,7s,9as,11ar)-7-{[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

C37H58O9 (646.4081)


   

(1r,3r,3as,5ar,7s,9as,11ar)-7-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2s)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

(1r,3r,3as,5ar,7s,9as,11ar)-7-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-[(2s)-6-methyl-5-methylideneheptan-2-yl]-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

C37H58O9 (646.4081)


   

2,2,6a,6b,9,9,12a-heptamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

2,2,6a,6b,9,9,12a-heptamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(2s,4s,5r,6s,9s,12r,13r,16s,18r)-2,6,13,17,17-pentamethyl-6-(4-methylpentyl)-8-oxo-16-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-1(20)-en-4-yl acetate

(2s,4s,5r,6s,9s,12r,13r,16s,18r)-2,6,13,17,17-pentamethyl-6-(4-methylpentyl)-8-oxo-16-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-1(20)-en-4-yl acetate

C37H58O9 (646.4081)


   

(2r,3r,4s,5r)-2,4,5-trihydroxyoxan-3-yl (2r,4e)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylhept-4-enoate

(2r,3r,4s,5r)-2,4,5-trihydroxyoxan-3-yl (2r,4e)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylhept-4-enoate

C37H58O9 (646.4081)


   

(2s,6r)-6-[(1r,3as,5ar,6s,7r,9as,11s,11ar)-7-{[(3r)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,6s,7r,9as,11s,11ar)-7-{[(3r)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-6-(hydroxymethyl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O9 (646.4081)


   

16-{4-[2,4-dihydroxy-5-methyl-6-(penta-1,3-dien-1-yl)oxan-2-yl]-3-hydroxypentan-2-yl}-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

16-{4-[2,4-dihydroxy-5-methyl-6-(penta-1,3-dien-1-yl)oxan-2-yl]-3-hydroxypentan-2-yl}-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

C37H58O9 (646.4081)


   

7-{[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-(6-methyl-5-methylideneheptan-2-yl)-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

7-{[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3-hydroxy-9a,11a-dimethyl-1-(6-methyl-5-methylideneheptan-2-yl)-6-methylidene-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-3a-carboxylic acid

C37H58O9 (646.4081)


   

methyl (2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,7r,8as,12as,14ar,14br)-7-hydroxy-4,4,6a,6b,8a,11,11,14b-octamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylate

methyl (2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,7r,8as,12as,14ar,14br)-7-hydroxy-4,4,6a,6b,8a,11,11,14b-octamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylate

C37H58O9 (646.4081)


   

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4r,5s)-5-(acetyloxy)-3,4-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4r,5s)-5-(acetyloxy)-3,4-dihydroxyoxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H58O9 (646.4081)


   

(2r)-2-[(1r,3ar,4r,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

(2r)-2-[(1r,3ar,4r,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

C37H58O9 (646.4081)


   

2-[(1r,3s,4s,7r,9s,12r,14s,17r,18r,19r,21r,22s)-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-22-yl]propan-2-yl acetate

2-[(1r,3s,4s,7r,9s,12r,14s,17r,18r,19r,21r,22s)-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-22-yl]propan-2-yl acetate

C37H58O9 (646.4081)